The Impact of Brexit on Pharmaceuticals and HTA

Lorgelly, Paula

doi:10.1007/s41669-018-0072-5

Cited by 5 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of course, added to this, there is the uncertainty of how medicines will be licensed in the UK following departure from the EU in 2019, and how, in turn, this will affect the current NICE drug appraisal process [ 13 ].…”

Section: Current Uncertaintiesmentioning

confidence: 99%

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Dickson

Boland

Duarte

et al. 2018

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Section: Current Uncertaintiesmentioning

confidence: 99%

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Dickson

Boland

Duarte

et al. 2018

Appl Health Econ Health Policy

View full text Add to dashboard Cite

“…We do not yet fully know what the impact of the COVID-19 pandemic will be on trade and supply of medicines, including raw materialsthere needs to be urgent research in this area to inform how we can support Commonwealth countries to deliver essential healthcare. This knowledge of the vulnerabilities in our medicines supply process will remain useful beyond the pandemic, as issues of access and affordability are relevant to any major global and political changes, such as with Brexit [40].…”

Section: Tradementioning

confidence: 99%

Together we unite: the role of the Commonwealth in achieving universal health coverage through pharmaceutical care amidst the COVID-19 pandemic

Chan

Rutter²,

Ashiru‐Oredope³

et al. 2020

J of Pharm Policy and Pract

View full text Add to dashboard Cite

The world currently faces unprecedented health challenges as COVID-19 poses a huge threat to health systems, economies and societies as we know it. The events of the current COVID-19 pandemic have further emphasised existing issues within our health systems. There is no better time than now to come together in global solidarity to tackle these evolving threats of COVID-19 pandemic. The Commonwealth is an ideally placed network to tackle these global health challenges, with its wide-reaching networks of governmental, non-governmental and civil society organisations across all continents. Although the biennial Commonwealth Heads of Government Meeting (CHOGM) originally scheduled to take place in Kigali in Rwanda 22-27 June 2020 has been postponed in view of COVID-19, Commonwealth country discussions are continuing, centred on the CHOGM key theme of 'Delivering a Common Future: Connecting, Innovating, Transforming', and five subthemes of Information and Communications Technology (ICT) and Innovation; Trade; Environment; Governance and the Rule of Law; and Youth. The planned CHOGM and Commonwealth itself provides all members a timely platform to consider innovative ways to connect, innovate and transform healthcare to meet the needs of their populations. This commentary considers these five CHOGM subthemes and how member nations can be supported to achieve universal health coverage through optimising medicines use and outcomes, in the midst of a global pandemic in line with the global health agenda.

show abstract

“…This will affect the evidence base for Health Technology Assessments due to less access to European research funding, as well as possibly increasing the cost of medicines and healthcare due to the expense of doing business as a small country. (13) It can be seen that the availability of possibly life-saving medication has become increasingly dependent on economic factors, especially in a resource-poor publicsector climate. It is considered a doctor's decision to recommend treatment if deemed appropriate, but there are several notable cases where such clinical decisions have been undermined or delayed.…”

Section: Nhs and Nicementioning

confidence: 99%

Is the pharmaceutical industry overpowering the medical profession?

Din

Kordowicz

2019

The British Student Doctor Journal

View full text Add to dashboard Cite

Doctors' reported loss of autonomy in the current policy climate and the subsequent deprofessionalisation of medicine can be attributed to many factors. The pharmaceutical industry accounts for a large proportion of healthcare costs, with the professional relationship between the industry and medical profession raising ethical concerns. Developing potentially life-saving products and potentiating scientific advances are some of the many good attributes of the pharmaceutical industry. The dependence of medical care on the production of pharmaceuticals is undeniable. However, it could be argued that the pharmaceutical industry takes advantage of this relationship, fuelled by financial motive. Conversely, there could be a complex interplay of factors driving a power imbalance in the pharma/clinical relationship. By reviewing literature in the field, this viewpoint article explores these multifaceted factors.

show abstract

The Impact of Brexit on Pharmaceuticals and HTA

Cited by 5 publications

References 20 publications

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Together we unite: the role of the Commonwealth in achieving universal health coverage through pharmaceutical care amidst the COVID-19 pandemic

Is the pharmaceutical industry overpowering the medical profession?

Contact Info

Product

Resources

About